Two Sigma Advisers
CNTX icon

Two Sigma Advisers’s Context Therapeutics CNTX Stock Holding History

Two Sigma Advisers’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,200
Closed -$9.11K – 2426
2023
Q1 		$9.11K Buy
+16,200
New +$12.3K ﹤0.01% 2547
2022
Q4 		– Sell
-13,400
Closed -$15K – 2539
2022
Q3 		$15K Buy
+13,400
New +$24.1K ﹤0.01% 2460

Other funds holding CNTX

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CHAM
Clear Harbor Asset Management Stamford, Connecticut $1.45B AUM 23.7% 1-Year Est. Return

Two Sigma Advisers's CNTX Position: Q2 2023 in Review

Two Sigma Advisers sold out of Context Therapeutics (CNTX) in Q2 2023, closing a stake of 16,200 shares — an estimated $9.11K sold.

Two Sigma Advisers first reported a position in CNTX in Q3 2022 and held it in 2 quarters. The position peaked at $15K in Q3 2022. 22 funds tracked by Wall St. Rank hold CNTX as of Q2 2023.

  • Two Sigma Advisers reported no remaining Context Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 16,200 Context Therapeutics shares in Q2 2023, an estimated $9.11K.
  • Two Sigma Advisers first reported a position in Context Therapeutics in Q3 2022 and held it in 2 quarters.
  • Two Sigma Advisers's Context Therapeutics position peaked at $15K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.